Applicant, as named in the Orange Book

Neurocrine

Neurocrine Biosciences Inc · Nasdaq: NBIX

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Ingrezza on 10 Aug 2040. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Ingrezza NDA 209241 · 3 strengths valbenazine tosylate	valbenazine tosylate	10 Aug 2040 patent, carve-out possible	patent, carve-out possible
Ingrezza Sprinkle NDA 218390 · 3 strengths valbenazine tosylate	valbenazine tosylate	10 Aug 2040 patent, carve-out possible	patent, carve-out possible
Crenessity NDA 218808 · 3 strengths crinecerfont	crinecerfont	12 Jan 2043 patent	patent
Crenessity NDA 218820 crinecerfont	crinecerfont	12 Jan 2043 patent	patent

Ingrezza · Generic tentatively approved · ANDA 215984, Teva Pharms IncTentative approval 21 Jan 2026Detected 25 Oct 2026